ARTELO BIOSCIENCES Seeks Shareholder Approval for Highly Dilutive $25M Equity Purchase Agreement
ARTL is trading near its 52-week low of $1.03 (8.7% above the low) on light trading volume (0.1× avg).
Summary
Artelo Biosciences is formally asking shareholders to approve a highly dilutive equity financing agreement with Square Gate Capital, enabling the company to issue over 20% of its stock at a discount to raise up to $25 million (potentially $50 million) in capital.
Key Events · Financing and Capital Events · ARTL
-
Shareholder Vote on Dilutive Financing
Shareholders are being asked to approve the issuance of over 20% of common stock to Square Gate Capital Master Fund, LLC – Series 5, as required by Nasdaq rules. This proposal was previously previewed in a PRER14A filing on 2026-06-22.
-
Enabling $25M+ Equity Purchase Agreement
This approval will allow the company to fully utilize an existing Equity Purchase Agreement (EPA) to sell up to $25 million (with an option for an additional $25 million) in common stock.
-
Discounted Share Issuance
Shares will be sold to Square Gate at a discount, specifically 95% of the lowest daily VWAP or lowest traded price during valuation periods.
-
Critical Capital for Going Concern
The proceeds from this financing are intended for working capital and general corporate purposes, crucial for a company operating under a "going concern" warning.
Analysis · ARTL · Life Sciences
This filing is a definitive additional proxy statement seeking shareholder approval for a new Proposal 3. This proposal asks shareholders to approve the issuance of more than 20% of the company's outstanding common stock to Square Gate Capital Master Fund, LLC – Series 5, as required by Nasdaq rules. This approval is crucial to enable the company to fully utilize its existing Equity Purchase Agreement (EPA) with Square Gate, which allows the company to sell up to $25 million (with an option for an additional $25 million) in common stock at a discount to market prices. Given the company's ongoing "going concern" warning and its small market capitalization, this financing is vital for its operations but will result in substantial dilution for existing shareholders.
At the time of this filing, ARTL was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.03 to $85.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.